Radiation-induced Parotid Gland Atrophy in Patients with Head and Neck Cancer After Carbon-ion Radiotherapy

Morikawa, Takamichi; Koto, Masashi; Hasegawa, Azusa; Takagi, Ryo; Fujikawa, Akira; Tsuji, Hiroshi; Shibahara, Takahiko; Kamada, Tadashi

doi:10.21873/anticanres.11116

Cited by 9 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[28] Different dose metrics have been explored as well such as: keeping the mean dose of an individual parotid gland to less than 44.7 Gy[27]; and keeping V5 <18.7% in a study of HNC patients treated with C-ion therapy examining decrease in parotid volume. [29]…”

Section: Resultsmentioning

confidence: 99%

Revisiting the dose constraints for head and neck OARs in the current era of IMRT

Brodin

Tomé

2018

Oral Oncology

View full text Add to dashboard Cite

Head and neck cancer poses a particular challenge in radiation therapy, whilst being an effective treatment modality requires very high doses of radiation to provide effective therapy. This is further complicated by the fact that the head and neck region contains a large number of radiosensitive tissues, often resulting in patients experiencing debilitating normal tissue complications. In the era of intensity-modulated radiation therapy (IMRT) treatments can be delivered using non-uniform dose distributions selectively aimed at reducing the dose to critical organs-at-risk while still adequately covering the tumor target. Dose-volume constraints for the different risk organs play a vital role in one’s ability to devise the best IMRT treatment plan for a head and neck cancer patient. To this end, it is pivotal to have access to the latest and most relevant dose constraints available and as such the goal of this review is to provide a summary of suggested dose-volume constraints for head and neck cancer RT that have been published after the QUANTEC reports were made available in early 2010.

show abstract

Section: Resultsmentioning

confidence: 99%

Revisiting the dose constraints for head and neck OARs in the current era of IMRT

Brodin

Tomé

2018

Oral Oncology

View full text Add to dashboard Cite

show abstract

“…При воздействии дозы ионизирующего излучения >10 Гр отмечают проявления ксеростомии разной степени тяжести у всех пациентов со ЗНО ЧЛО [5,6,13,18,21]. При суммарной дозе облучения (СОД) более 30 Гр проявления ксеростомии считают уже необратимыми [10,22].…”

Section: влияние ионизирующего излучения на структуру и функцию сж паunclassified

Radiation-associated changes in salivation of patients with cancer of maxillofacial region

Bykov¹,

Izhnina²,

Кочурова³

et al. 2018

Stomat.

View full text Add to dashboard Cite

show abstract

“…Contrary to XRT, in which case both parotid glands are irradiated as part of the prophylactic irradiation of lymph nodes, both parotids are rarely irradiated in CIRT. One study observed cases of mild xerostomia development after CIRT and implied that xerostomia might be associated with parotid gland atrophy 20 . The study investigated the relationship between DVH parameters and parotid gland atrophy for 54 patients treated with 57.6 or 64 Gy (RBE) in 16 fractions, whose parotid glands were irradiated during CIRT.…”

Section: Parotid Glandsmentioning

confidence: 99%

“…Previous studies have associated various constraints with OAR complications related to the HN cancer CIRT 2,17–31 . This review provides an extensive list of constraints for HN cancer CIRT based on the Japanese RBE models.…”

Section: Introductionmentioning

confidence: 99%

Dose–volume constraints for head‐and‐neck cancer in carbon ion radiotherapy: A literature review

et al. 2023

View full text Add to dashboard Cite

Head-and-neck (HN) tumors are ranked as the sixth most common malignancy worldwide. Treatment options depend on the stage, anatomical site, and surgical accessibility of the HN tumors. 1 Depending on the stage, squamous cell carcinomas (SCCs) can be treated with surgery, radiotherapy, or a combination of surgery, radiotherapy, and/ or chemotherapy. On the other hand, non-SCCs, being usually resistant to chemotherapy and radiotherapy, have limited treatment options. 2 Carbon ion radiotherapy (CIRT) has various advantages compared with X-ray radiotherapy (XRT). It has higher biological effectiveness than XRT and has already shown promising results for the treatment of resistant tumors like sarcoma, adenocarcinoma, and other non-SCCs. [3][4][5]

show abstract

Radiation-induced Parotid Gland Atrophy in Patients with Head and Neck Cancer After Carbon-ion Radiotherapy

Abstract: Abstract. Background/Aim: This study aimed to clarify the relationship between dosimetric factors and parotid gland (PG) atrophy after carbon ion radiotherapy (C-ion RT

Cited by 9 publications

References 7 publications

Revisiting the dose constraints for head and neck OARs in the current era of IMRT

Revisiting the dose constraints for head and neck OARs in the current era of IMRT

Radiation-associated changes in salivation of patients with cancer of maxillofacial region

Dose–volume constraints for head‐and‐neck cancer in carbon ion radiotherapy: A literature review

Contact Info

Product

Resources

About